Search Bar & Filters
Found 125 Actively Recruiting clinical trials
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
Researchers are evaluating LNCB74, an antibody drug conjugate, in an open-label Phase 1 study involving participants with advanced solid tumors including ovarian, breast, endometrial, non-small cell lung cancers, and other metastatic solid tumors. The study aims to determine the safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose of LNCB74. Participants receive LNCB74 intravenously in 21-day cycles. The study is conducted in two parts Part 1 involves dose escalation to find the maximum tolerated and administered doses, including backfilling for safety and biomarker data. Part 2 focuses on dose expansionoptimization to evaluate safety, anti-tumor activity, and pharmacodynamics in a more uniform tumor population, establishing the recommended doses for future studies. Throughout the study, participants undergo assessments including tumor tissue sampling, fresh biopsies if archival samples are unavailable, and evaluations of tumor response, safety, and pharmacokinetics over a period of up to 24 months. Researchers monitor immunogenicity, disease control, progression-free survival, and drug concentration parameters to better understand treatment effects and tolerability.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effects of memantine as a single agent in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma HCC who are not candidates for intensive systemic therapy. This phase 2 and 3 prospective study focuses on patients with cirrhosis having a Child-Pugh score of B7 or higher, aiming to describe multiple efficacy endpoints including progression-free survival and changes in quality of life during treatment. Participants receive memantine starting at 5 mg by mouth once daily, with dose escalation up to 20 mg daily. This single-group study includes patients newly diagnosed with HCC confirmed by histology or imaging, who have measurable lesions and are not eligible for aggressive systemic treatments. The treatment continues while monitoring various outcomes over time. During the study, participants undergo regular assessments including evaluation of tumor progression and quality of life. Researchers monitor progression-free survival at six months as the primary outcome. Patients are also required to meet specific health criteria and agree to use contraception if applicable. The study lasts until July 2029, with ongoing monitoring of efficacy and safety throughout the participation period.
Actively Recruiting
Researchers are evaluating the safety and performance of MagnetOs Putty and MagnetOs Easypack Putty compared to autogenous bone graft in patients undergoing hindfoot or ankle fusion surgeries. This phase IV post-marketing study focuses on people with hindfoot and ankle disorders who require surgical fusion using rigid hardware fixation and supplemental bone grafts. The study aims to assess these treatments following the latest Instructions For Use in foot and ankle procedures. Participants will be randomly assigned to receive either MagnetOs PuttyEasypack Putty or autograft bone from specific sites such as the calcaneus or tibia during their fusion procedure. The study includes various fusion surgeries like ankle fusion, subtalar fusion, calcaneocuboid fusion, talonavicular fusion, or double fusion. The volume of MagnetOs or autograft used depends on the joint, with specific amounts for the tibiotalar joint and other joints. Participants will be followed closely after surgery with visits at discharge, and at 2, 6, 12, 24, and 52 weeks post-operation. Assessments include radiographic imaging with X-rays and CT scans to evaluate bone fusion, especially at 24 and 52 weeks. Functional evaluations and safety monitoring continue for one year. Imaging becomes weight bearing starting at week 12, and secondary surgeries may alter the imaging schedule.
Actively Recruiting
Researchers are evaluating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure. The study focuses on individuals with preserved ejection fraction and left ventricular hypertrophy. It is a phase 2, randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of CDR132L on reversing cardiac remodeling. Participants will be randomly assigned to receive one of three different doses of CDR132L or a placebo. All treatments are given as intravenous infusions once every 4 weeks for 48 weeks. Throughout the study, participants will continue their individually tailored guideline-directed standard care therapy for heart failure. The trial duration is about 60 weeks. During the study, participants will undergo various assessments, including measuring changes in microRNA-132 levels as the primary outcome at 24 weeks. Secondary outcomes include changes in heart structure measured by cardiac magnetic resonance imaging and blood biomarkers, as well as monitoring adverse events up to 60 weeks. Participants will receive regular infusions and attend scheduled visits for monitoring and safety evaluations.
Actively Recruiting
Researchers are comparing two chemotherapy approaches combined with standard surgery and radiation in patients newly diagnosed with intermediate-risk rhabdomyosarcoma. This phase III trial evaluates whether a higher dose chemotherapy over a shorter time performs better or differently than a lower dose chemotherapy with maintenance over a longer period. The study also examines survival rates, treatment side effects, and molecular features of the cancer. Participants are randomly assigned to one of two treatment regimens. Regimen A involves vincristine, dactinomycin, and a higher dose of cyclophosphamide given intravenously over multiple 21-day cycles, with possible surgery in week 12 and radiation during later cycles. Regimen B uses a lower cyclophosphamide dose alternating with vincristine and irinotecan, followed by 24 weeks of maintenance chemotherapy with vinorelbine and oral cyclophosphamide. Both groups undergo imaging scans and may have biopsies during the study. Throughout the trial, participants attend scheduled visits for chemotherapy administration, imaging CT, MRI, PET, blood and other sample collections, and monitoring of side effects. After treatment, follow-up visits occur every 3 months for the first year, then less frequently over 5 years. Researchers measure event-free survival, overall survival, local tumor control, treatment-related adverse events, and timely molecular biomarker reporting. Biospecimens are collected for future research and fertility preservation is assessed.
Actively Recruiting
Researchers are evaluating siplizumab, an anti-CD2 monoclonal antibody, compared to rabbit anti-thymocyte globulin rATG to prevent kidney transplant rejection in adults with end stage kidney disease. This phase 2b study focuses on safety, dosing, and effectiveness in helping the body accept a kidney transplant while participants also receive standard immunosuppressive therapy. The trial will enroll approximately 120 participants who need induction therapy for kidney transplantation. Participants will be randomly assigned to one of three groups two groups will receive different doses of siplizumab, and the third group will receive rATG. All participants will continue standard anti-rejection medicines before, during, and after transplant, including tacrolimus, mycophenolic acid, and corticosteroids. Premedications to reduce reaction risks and infection prevention treatments will also be given. The treatment period includes the transplant hospitalization and subsequent monitoring. Participants will provide medical and medication histories and undergo physical exams, vital sign checks, blood tests, and heart electrical activity monitoring ECG at the first visit and throughout the study. Safety assessments include viral monitoring and lab tests. Follow-up visits will continue for 12 months after transplant to monitor safety and transplant success. Researchers will measure adverse events, transplant rejection, graft function, and how the body responds to the study drugs.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating how well different doses of the medicine BI 3812465 are tolerated in adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study includes two parts an initial phase testing low, medium, and high doses sequentially, followed by a phase where more participants receive these doses in a randomized way to assess safety and tolerability. Participants receive BI 3812465 as injections into the back of the eye, with a total of three injections given during the study. In Part 1, a small group receives increasing doses starting from low, and in Part 2, a larger group is randomized to receive one of the three dose levels. The treatment period involves these injections, and dosing only advances if lower doses are tolerated. Participants stay in the study for up to 7 months, attending 19 visits to the study site or, when possible, having visits at their home. During these visits, doctors check the severity of the eye condition and monitor for any health problems related to the medicine. The study measures dose limiting events, ocular adverse events, and other safety outcomes throughout the treatment and follow-up period.
1-10 of 125
1